anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to Baoling tea for preventing and treating thrombotic diseases and a preparing process thereof. The Baoling tea is a combination of Chinese herbal medicines in a mode of tea diet therapy and is characterized in that the Baoling tea comprises 0.05 to 0.1g of radix glycyrrhiza, 0.05 to 0.1g of wild chrysanthemum, 1 to 2g of barley, 2 to 4g of red sage root, 1 to 2g of Gynostemma pentaphylla, 0.5 to 1.5g of ginkgo leaf, 0.1 to 0.5g of rhubarb and 0.2 to 0.8g of hawthorn fruit; 6g of the Chinese herbal medicines is packaged into one bag. The Chinese herbal medicines are pulverized into powder with 40 to 80 meshes. The Baoling can prevent and treat thrombotic diseases and relatively relieve hypertension, hyperlipemia and hyperglycemia along with thrombotic diseases. The Baoling tea changes traditional customs of medicine administration, body building and nourishment while in diseases in a mode of tea diet therapy, the combination of thrombus prediction and the tea diet therapy of the Baoling tea can control and relieve the state of diseases and realize the health of constitution and longevity. The price of Baoling tea is 1/10 of that of a common medicine and is 1/20 to 1/50 of that of an import medicine, and thus, the Baoling tea is accepted by common people. Practice and investigation at certain places show that the present invention provides a piece of good news for human health.
The usual starting dose of tolazamide tablets for the mild to moderately severe type II diabetic patient is 100-250 mg daily administered with breakfast or the first main meal. Generally, if the fasting blood glucose is less than 200 mg/dl, the starting dose is 100 mg/day as a single daily dose. If the fasting blood glucose value is greater than 200 mg/dl, the starting dose is 250 mg/day as a single dose. If the patient is malnourished, underweight, elderly, or not eating properly, the initial therapy should be 100 mg once a day. Failure to follow an appropriate dosage regimen may precipitate hypoglycemia. Patients who do not adhere to their prescribed dietary regimen are more prone to exhibit unsatisfactory response to drug therapy.
All participants will be randomly assigned to receive the potato regimen daily for the 12-week treatment period, separated by a 2-week washout.The potato regimen (75 grams of baked white russet potato with the skin) and refined grain (100 grams of long grain white rice) regimen will be matched for calories, carbohydrate and fat content and will both contribute to approximately 100 kilocalories, 22g carbohydrates, and 0.2g of fat. In order to increase participants' compliance, they will be informed of a variety of ways to consume their regimen. The rationale for choosing this amount of potato and rice regimen is based on the common practice of carbohydrate counting practiced by dietitians and diabetes educators in clinical settings, where 45-60 g of carbohydrates should be consumed at each meal and 15-20 g of carbohydrates can be consumed at each snack throughout the day.
INTRODUCTION: Despite the growing body of literature on sacral neuromodulation (SNM) outcomes, research focusing on male patients remains limited and often represented by small cohorts nested within a larger study of mostly women. Herein, we evaluated the outcomes of SNM in a male-only cohort with overactive bladder (OAB), fecal incontinence (FI), chronic bladder pain, and neurogenic lower urinary tract dysfunction (NLUTD).
MATERIALS AND METHODS: This retrospective cohort study included 64 male patients who underwent SNM insertion between 2013 and 2021 at a high-volume tertiary center. Indications for SNM therapy included OAB, FI, chronic pelvic pain, and NLUTD. Descriptive statistics, Fisher's and t-test were used in analysis.
RESULTS: The mean age was 57.7 ± 13.4 years, and the most frequent reason for SNM insertion was idiopathic OAB (72%), FI (16%), pelvic pain (11%), and NLUTD (11%). A majority (84%) of men received treatment prior to SNM insertion. 84% reported satisfaction and 92% symptom improvement within the first year, and these improvements persisted beyond 1 year in 73% of patients. Mean follow up was 52.7 ± 21.0 months. The complication rate was 23%, and the need for adjunct treatments was significantly reduced (73% to 27%, p < 0.001). Treatment outcomes did not differ significantly between various indications for SNM therapy or the presence of benign prostatic hyperplasia (BPH).
CONCLUSION: SNM is an effective and safe procedure for male patients with neurogenic and non-neurogenic OAB, pelvic pain, and FI. Over 70% of patients experienced symptomatic improvement and remained satisfied in the mid to long term follow up. BPH does not seem to hinder treatment outcomes.
The invention discloses a cashew accessory fruit flavor Lonicera fragrantissima subsp. standishii fruit wine. The cashew accessory fruit flavor Lonicera fragrantissima subsp. standishii fruit wine is made by adopting cashew accessory fruit and Lonicera fragrantissima subsp. standishii fruit as raw materials and adding Osbeckia opipara C. Y. Wu et C. Chen and Styrax dasyanthus. The nutrition values of the cashew accessory fruit and the Lonicera fragrantissima subsp. standishii fruit are fully used, and the cashew accessory fruit and the Lonicera fragrantissima subsp. standishii fruit are combined with traditional Chinese medicines to realize synergistic effects and spleen invigorating and stomach benefiting effects. The cashew accessory fruit, the Lonicera fragrantissima subsp. standishii fruit and a traditional Chinese medicine juice undergo enzymatic hydrolysis by using pectase in order to remove the inherent bitterness in a mixture, so the produced wine has sour-sweet and palatable taste, heavy alcohol fragrance, overflowing fragrance and protruding health functions, and can be taken for a long term to obviously improve spleen and stomach weakness people's discomfort. A making method of the wine has the advantages of simplicity, easiness in realization, meeting of people's demands of the health, and realization of batch production.
FIELD: biologically active peptides. SUBSTANCE: invention provides peptide analogs of glucagons-like peptide having formula:  , where all radicals are defined in claims. Compounds show high GLP- 1 activity and can be used for treating diabetes, obesity, and other conditions associated with GLP-1 metabolism disturbances. Pharmaceutical compositions containing indicated peptide analogs are also described. EFFECT: expanded therapeutic possibilities of peptides. 12 cl, 2 tbl, 411 ex
Investigators will use Veteran Health Administration (VHA) electronic health record (EHR) data to construct patient-level Framingham stroke risk scores using previously validated methodology. Investigators will establish a cohort of live patients with at least one primary care visit 12 months prior to study initiation (Oct 1, 2015). Investigators will obtain EHR data for Framingham measurements of age, sex, systolic blood pressure (SBP), blood pressure treatment (yes/no), total cholesterol, high-density lipoprotein cholesterol, and smoking status in the prior 12 month period. SBP will be obtained from outpatient primary care visits only; if \> 1 SBP is available the investigators will use the average of the last 2 outpatient SBPs prior to study initiation.
In this study, we investigated the outcome of goal attainment in individual and group-based neuropsychological intervention for young adults with dyslexia. Participants (N = 120) were randomly assigned to individual intervention, group intervention, or wait-list control group. Attainment of goals set personally before the intervention was evaluated after the intervention using Goal Attainment Scaling. The participants were asked to report the number of concrete changes made in their study or working habits at five months (after intervention or wait-list control time), at ten months, and 15 months post-interventions. Potential predictive factors for predicting goal attainment were evaluated including background and cognitive variables, self-reported psychological variables (mood, cognitive and behavioral strategies, self-esteem, quality of life), and self-reported behavioral variables (concrete changes made, time used to work on intervention matters). Based on the results, personal goals were, on average, met especially in individual intervention. Nearly 50% of goal attainment was explained by intervention type, behavioral and cognitive strategies, concrete changes made, cognitive capacity, and used time. Concrete changes, e.g., adopting new strategies and methods in study or working habits, were reported in both interventions and more than during the wait-list control period. The changes seemed long-lasting as fifteen months post-intervention, 76.4% reported still using the learned strategies. A structured and relatively short neuropsychological intervention for dyslexia in either individual or group format can lead to attaining pre-set personal goals and positive behavioral changes that can last up to over a year post-intervention.
Methods, systems, and apparatuses are described for clinical system integration. For example, a computing device may receive a request based on one or more of a plurality of clinical systems. The computing device may retrieve, based on the request, a first plurality of interface components. The first plurality of interface components may be retrieved from each of the plurality of clinical systems in real-time. The computing device may convert the first plurality of interface components to a second plurality of interface components. The second plurality of interface components may correspond to the computing device.
This study was approved by the Research Ethics Committee of Faculty of Dentistry Beni-Suef University (ID #FDBSUREC/27022019/AM) and was conducted in full accordance with the World Medical Association Declaration of Helsinki 1975, revised in 2003. The questionnaire was anonymous with no personal identification data. Completion and submission of the questionnaire was considered an approved informed consent to participate in the study by the Research Ethic Committee.

The questionnaire was designed by the authors and pilot tested among a group of 12 periodontists for validation. Afterwards, adjustments were made to ensure a clear and comprehensive version of the questionnaire. The questionnaire had a cover letter explaining the nature and purpose of the survey and comprised 15 questions. The first six statements of the questionnaire were descriptive in nature addressing the participant's demographics, and the seventh was a question whether the participant is aware of the new PDL classification or not. Only those who were aware of it were asked to proceed to 13 multiple choice questions using Likert scale; ranging from strongly disagree to strongly agree or from excellent to poor, in addition to "I don't know" option (8). There were also three open ended questions for further comments at the end of the questionnaire.
The investigators propose an open label trial of tattoo machine microneedling in ten patients with fibrosing alopecia (five patients with CCCA and five with FFA). Ten healthy female patients older than 18 years will undergo 6 microneedling sessions. Over the course of six months, subjects will undergo up to six treatment sessions (one session every 30 day). Photographs will be taken at each session. Patients will be evaluated at 8 visits over 8 months with the first visit for screening purposes. Each visit will last about an hour. Approximately 30 minutes will be spent on consenting and time for patient to ask questions during the first visit. The remaining 30 minutes will be allotted for the investigator to determine if the patient meets criteria for trial enrollment. During the remaining visits, 20 minutes will be allotted for photography, 15-20 minutes for the procedure and 10-15 minutes for post-procedure patient assessment. Remaining 10 minutes on visits 2 and 8 will be used for biopsy.
One Arm will be given Low Dye taping. The augmented low-Dye technique, involves applying a device consisting of a spur and mini-stirrups to the foot and then adding reverse sixes and calcaneal slings to an anchor on the distal one-third of the leg. A rigid 38-mm sports tape with zinc oxide adhesive will be used for all of the taping procedures. Prior to application of the tape, any hair in the region will be shaved and the foot and leg will be washed with soap and warm water to remove any dirt or oils that might decrease the adhesion of the tape. The Transverse Tibial Rotation (TTR) measurements will be repeated following application of tape.
Hip fractures significantly affect patients' health and quality of life. Despite therapeutic treatments, many patients continue to experience poor prognoses that include recurrent fractures and mortality, especially the older ones. Therefore, understanding important factors associated with post-fracture prognoses is critical. This study focuses on patients' multimorbidity trajectories and examines how the trajectory's time span, number of coexisting chronic diseases, and sequential disease patterns relate to distinct prognostic outcomes. From the National Health Insurance Research Database in Taiwan, we obtain a sample of 128,822 patients who suffered an initial hip fracture between 1996 and 2011. We use this sample to analyze the relationships between multimorbidity trajectories and prognostic outcomes after an initial hip fracture. The results reveal that a patient's multimorbidity trajectory's time span and number of chronic diseases significantly associate with his or her post-fracture prognosis. In addition, essential sequential patterns of chronic diseases relate to post-fracture prognoses too. We then leverage the discovered relationships to develop a cross-attention neural network method for estimating patients' post-fracture prognoses and demonstrate its predictive utilities relative to several prevalent machine leaning methods. This study underscores the importance of leveraging the time span, number of chronic diseases, and sequential disease patterns in patients' multimorbidity trajectory profile to estimate their prognoses within three years of an initial hip fracture, which can support physicians' clinical decisions and patient management.
Doxorubicin (DOX) is widely used in clinic as a broad-spectrum chemotherapy drug, which can enhance the efficacy of chemodynamic therapy (CDT) by interfering tumor-related metabolize to increase H2O2 content. However, DOX can induce serious cardiomyopathy (DIC) due to its oxidative stress in cardiomyocytes. Eliminating oxidative stress would create a significant opportunity for the clinical application of DOX combined with CDT. To address this issue, we introduced sodium ascorbate (AscNa), the main reason is that AscNa can be catalyzed to produce H2O2 by the abundant Fe3+ in the tumor site, thereby enhancing CDT. While the content of Fe3+ in heart tissue is relatively low, so the oxidation of AscNa had tumor specificity. Meanwhile, due to its inherent reducing properties, AscNa could also eliminate the oxidative stress generated by DOX, preventing cardiotoxicity. Due to the differences between myocardial tissue and tumor microenvironment, a novel nanomedicine was designed. MoS2 was employed as a carrier and CDT catalyst, loaded with DOX and AscNa, coating with homologous tumor cell membrane to construct an acid-responsive nanomedicine MoS2-DOX/AscNa@M (MDA@M). In tumor cells, AscNa enhances the synergistic therapy of DOX and MoS2. In cardiomyocytes, AscNa could effectively reduce the cardiomyopathy induced by DOX. Overall, this study enhanced the clinical potential of chemotherapy synergistic CDT.
PCT No. PCT/EP97/00127 Sec. 371 Date Jul. 22, 1998 Sec. 102(e) Date Jul. 22, 1998 PCT Filed Jan. 13, 1997 PCT Pub. No. WO97/27199 PCT Pub. Date Jul. 31, 1997There are described compounds of formula I wherein R1 and R2 are as defined in the description, Q is heterocyclyl boned via a ring nitrogen atom and having the formula IA wherein R3 and R4 and m and n are as defined in the description, the ring marked A is a heterocyclyl having 5 to 9 ring atoms and having at least one saturated bond, it being possible for a further ring hetero atom selected from O and S to be present in addition to the bonding nitrogen atom, the ring system marked B is a free or benzo-, thieno-, furo-, pyrrolo- or dihydropyrrolo-fused carbocyclic ring having from 5 to 9 carbon atoms that is fused to the ring A and may be unsaturated, partially saturated or fully saturated, and the bond marked by a parallel dotted line between the ring systems marked A and B is either a single bond or a double bond, and a salt thereof where at least one salt-forming group is present. The compounds are inhibitors of protein kinases and have, for example, antitumour activity.
ACT-Based Intervention and Activity Tracker WITH Feedback (Combining ACT and Behavioral Change) In the last experimental condition, obese individuals will follow the same rehabilitation program in the in-patients phase of the Behavioral Change condition, with the addition of the brief ACT intervention of 4 45-minutes sessions for a total amount of 3 hours one-to-one therapy sessions, exactly as in the ACT condition. In the out-patient phase of 16 weeks, each participant receive feedback from activity tracker following the same stepped protocol but message and feedbacks are informed by ACT therapist, including Value-based goal setting, prompt for including defusion from difficult thoughts, mindfulness cues and a set of ACT-consistent metaphors and messages.
PURPOSE: A method for preparing peptides with antibacterial activity is provided to produce a large amount of beta-defensin and to apply the defensin to pharmacy. CONSTITUTION: A method for in vitro expression of pig beta-defensin comprises: a step of performing PCR using a primer with cDNA derived from pig tissues; a step of treating the PCR product with restriction enzyme; a step of performing ligation of the PCR product into an expression vector; and a step of transforming the expression vector to a host cell. The primer has a base of sequence number 1 or 2. The beta-defensin has an amino acid sequence of sequence number 5. An antibacterial composition against pathogenic microorganism contains the beta-defensin. The pathogenic microorganism is gram-positive or gram-negative bacteria.
PURPOSE: In situ laser fenestration (ISLF) is a recently introduced technology that offers the potential to perform total endovascular treatment of aortic arch and thoracoabdominal aortic pathologies in the acute setting. This experiment's aim was to assess ISLF in some currently common aortic endografts and bridging stent-grafts.
MATERIALS AND METHODS: Three different aortic endografts were evaluated: (1) Zenith Alpha, (2) Zenith TX2, and (3) Conformable GORE TAG. Each endograft was submerged in 37°C saline to create fenestrations using the 308 nm CVX-300 Excimer Laser System fitted with a 2.3 mm diameter Turbo-Elite laser atherectomy catheter compatible with a 0.018″ guidewire. Three different 8 mm bridging stent-grafts were evaluated: (1) BeGraft peripheral, (2) BeGraft peripheral plus, and (3) GORE VIABAHN VBX Balloon Expandable. All bridging stent-grafts were deployed and exposed to different balloon sizes and pressures. The ISLFs and bridging stent-grafts were then evaluated for any tears, stenoses, and seal.
RESULTS: A laser fenestration was consistently rapidly obtained in the Zenith Alpha and the Zenith TX2 endografts while it proved difficult to achieve a timely fenestration in the C-TAG. No fabric tears were noted in the Zenith Alpha and Zenith TX2 when inflating Armada (Abbott) 8 mm balloon in the fenestrations with pressures up to 15 atmospheres (rated burst pressure) nor when flaring bridging stent-grafts with balloons up to 12 mm in diameter at 10 atmospheres, while major tears were frequently noted in the C-TAG when the Armada 8 mm balloons were inflated. BeGraft Peripheral and BeGraft Peripheral Plus were all firmly attached to the fenestrations showing good seal on manual testing, while every sixth VBX bridging stent-graft displayed poorer attachment to the fenestration before dilatation at high pressure. Commonly, significant stenoses remained in the bridging stent-grafts after dilatation at nominal pressure, which could only be eradicated with high-pressure balloons.
CONCLUSION: In this limited bench-test, Dacron endografts responded well to the ISLF technology. Satisfactory deployment of the bridging stent was noted only after inflation and/or flaring with high-pressure balloons. Further work with different types of commercially-available bridging stent-grafts and endografts to assess the durability of in situ fenestration (ISF) and bridging stents in ISF is recommended.
CLINICAL IMPACT: This report on experimental in situ laser fenestration provide important insights for clinicians considering using in situ laser fenestration of aortic stentgrafts in vivo. In particular, different laser settings were tested together with a selection of aortic stentgrafts. Also, the target pressure needed in PTA balloons to dilate the fenestrations and any subsequent tears in the fabric were noted. This was followed by deployment of assorted balloon-expandable stentgrafts with estimation of residual stenosis and seal.
Patients in the Qigong group receive Qigong,a mind-body exercise, 3 times a week, for 6 weeks during radiotherapy course. The participants are given a DVD contains Qigong program, and they attend the Qigong class in a health education room at the radiation oncology department to assure their attendance.
This is an observational study of clinical outcomes to be conducted in the United States. Patients with a diagnosis of Stage 3-4 advanced cancer who possess specific pathway mutations identified by the Guardant360® test will be eligible to enroll in the study. Patients will be recruited by telephone or email and/or through the Guardant Health Patient Portal to determine interest in the study. Should patients be interested in contributing to this registry study, they will be prompted to consent via a commercial service for patients to request, manage, and view their medical records. Enrolled participants will be requested to release copies of their medical records for review by the principal investigator. Study adminsitrators will abstract participant demographics, cancer-related therapies, and clinical outcomes for analysis.
Participants receive four $5 vouchers each valid for an entire month, starting in month 1 and continuing every month through month 6. The voucher can pay for any food but not tobacco, alcohol or prepared foods.
PROBLEM TO BE SOLVED: To impart even damaged hair with adequate wiriness, and raise the resistance to the moisture content change around the hair, suppressiveness against moisture spreading and antistaticity. SOLUTION: This method for treating the hair comprises treating the hair with a shampoo containing pref. 3-18 wt.% of an amino acid-based anionic active agent and pref. 0.2-20 wt.% of a sucrose fatty acid ester followed by treating the resultant hair with a hair-protective agent containing pref. 0.1-10 wt.% of a brominated type cationic active agent and pref. 0.2-20 wt.% of a sucrose fatty acid ester.
Dasatanib, 70 mg twice daily (BID), with dose escalation to 90 mg BID was allowed for participants who showed evidence of progression or lack of response. Up to 2 dose reductions were allowed for intolerance.